MINIject (MIGS)

Caution: investigational device not available for use or sale in the United States.

MINIjectTM is designed to significantly reduce IOP by enhancing aqueous humour outflow from the anterior chamber to the suprachoroidal space. Implantation is predictable in a single-step procedure using a deployment wheel.

MIGS implant
MINIject implanted in suprachoroidal space

MINIject exhibits all the advantages of the STAR® material such that it conforms to the eye anatomy, and benefits from sustained drainage efficacy over time due to bio-integration of surrounding tissues into the material. A natural flow speed results, which reduces the incidence of fibrosis, minimises scarring, and increases implant durability.

The MINIject first-in-human STAR-I clinical trial showed that the implantation of MINIject resulted in an average 32.6% IOP reduction to a mean of 15.6 mmHg at one year. In addition, 75% of patients were able to discontinue topical medication usage and remained medication-free at one year. There were no serious ocular adverse events and no patient required subsequent glaucoma surgery.